Clinical trials: in Poland
Carcinoma, Non-Small-Cell Lung
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to…
- Trial name
- SUNRAY-02 (NCT06890598)
- Testing
- Olomorasib, Pembrolizumab, Durvalumab
- Where
- 368 sites in United States, Australia and 27 more
- Volunteers
- 700 people
- Sponsor
- Eli Lilly and Company
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Symptomatic Genetic Dilated Cardiomyopathy
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM).
- Trial name
- KINSHIP-DCM (NCT07210723)
- Testing
- danicamtiv
- Where
- 79 sites in United States, Belgium and 9 more
- Volunteers
- 332 people
- Sponsor
- Kardigan, Inc.
Arrhythmia, Bradycardia
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival…
- Conditions
- Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
- Trial name
- PPR (NCT00271180)
- Testing
- Device
- Where
- 338 sites in United States, Australia and 33 more
- Volunteers
- 20,000 people
- Sponsor
- Medtronic
Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative…
- Trial name
- ELEGANT (NCT06492616)
- Testing
- Elacestrant, Anastrozole, Letrozole
- Where
- 555 sites in United States, Argentina and 26 more
- Volunteers
- 4,556 people
- Sponsor
- Stemline Therapeutics, Inc.
Rectal Cancer, Sigmoid Colon Cancer
Indocyanine Green Lymphatic Mapping in Minimally Invasive Sigmoid and Rectal Cancer Surgery
This prospective, single-center, non-randomized study with a historical control group evaluated the clinical utility of indocyanine green-guided lymphatic mapping (ICG-LM) during minimally invasive surgery for sigmoid colon and…
- Trial name
- NCT07916532
- Testing
- Intraoperative ICG-Guided Lymphatic Mapping
- Where
- Poland
- Volunteers
- 29 people
- Sponsor
- Jagiellonian University
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes.
- Trial name
- ENLIGHTEN-2 (NCT07282600)
- Testing
- Eloralintide
- Where
- 143 sites in United States, China and 11 more
- Volunteers
- 1,035 people
- Sponsor
- Eli Lilly and Company
Immune Thrombocytopenia (ITP)
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur.
- Trial name
- NCT06721013
- Testing
- Pirtobrutinib
- Where
- 43 sites in United States, China and 8 more
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with…
- Trial name
- NCT06672939
- Testing
- Orforglipron
- Where
- 34 sites in United States, Israel and 4 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur.
- Trial name
- NCT07533006
- Testing
- LY4005130
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Athletic Performance, Cognitive Fatigue
TCP-600 Supplementation and Performance Response in Professional Football Players
This 28-day randomised, placebo- and active-controlled trial investigated multidimensional responses to taurine-caffeine supplementation with or without phosphatidylserine in 65 male professional and highly trained football…
- Conditions
- Athletic Performance, Cognitive Fatigue, Exercise Recovery, Football-Specific Performance
- Trial name
- TCP600-RESP (NCT07710547)
- Testing
- Taurine, Caffeine, Phosphatidylserine
- Where
- 3 sites in Poland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Vizja University in Warsaw
Lymphoma, Non-Hodgkin, B-cell Lymphoma
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies.
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- BAF_FRontier-1 (NCT07101328)
- Testing
- LY4152199 - IV
- Where
- 51 sites in United States, Australia and 10 more
- Volunteers
- 215 people
- Sponsor
- Eli Lilly and Company
Knee Osteoarthritis
Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA
This randomized, double-blind, controlled trial is designed to compare the analgesic efficacy and safety of perineural dexamethasone versus perineural dexmedetomidine as adjuvants to ropivacaine for ultrasound-guided interspace…
- Trial name
- NCT07386600
- Testing
- Ropivacaine 0.2% Injectable Solution, Dexamethasone 4mg, Dexmedetomidine
- Where
- Poland
- Volunteers
- 96 people
- Sponsor
- Poznan University of Medical Sciences
Diffuse Large B-cell Lymphoma (DLBCL)
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy.
- Trial name
- OLYMPIA-3 (NCT06091865)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 195 sites in United States, Australia and 19 more
- Volunteers
- 904 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT07218341
- Testing
- Pirtobrutinib, Idelalisib
- Where
- 50 sites in United States, Australia and 15 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Colitis, Ulcerative, Crohn Disease
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group.
- Trial name
- NCT07483073
- Testing
- Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
- Where
- 71 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and…
- Trial name
- COMMIT-CD (NCT06937099)
- Testing
- Mirikizumab, Tirzepatide
- Where
- 183 sites in United States, Austria and 20 more
- Volunteers
- 290 people
- Sponsor
- Eli Lilly and Company
Intra-Abdominal Hypertension, Abdominal Compartment Syndrome
WSACS 2026 Delphi Consensus on the Practical Management of Intra-abdominal Hypertension and Abdominal Compartment Syndrome
The Abdominal Compartment Society (WSACS) is updating its 2013 clinical practice guidelines on intra-abdominal hypertension (IAH) and the abdominal compartment syndrome (ACS).
- Trial name
- WSACS-DELPHI-2 (NCT07915362)
- Testing
- Delphi structured interview via online survey
- Where
- Poland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Medical University of Lublin
Chronic Rhinosinusitis Without Nasal Polyps
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
- Trial name
- BiRCh (NCT06013241)
- Testing
- Brensocatib, Mometasone furoate nasal spray (MFNS)
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 288 people
- Sponsor
- Insmed Incorporated
Advanced Cancer, Metastatic Cancer
FS222 First in Human Study in Patients With Advanced Malignancies
This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222.
- Trial name
- NCT04740424
- Testing
- FS222
- Where
- 21 sites in Australia, Georgia and 5 more
- Volunteers
- 260 people
- Sponsor
- invoX Pharma Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.